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Abstract
Mutations in the splicing factor SF3B1 are found in several cancer types and have been as-
sociated with various splicing defects. Using transcriptome sequencing data from chronic
lymphocytic leukemia, breast cancer and uveal melanoma tumor samples, we show that
hundreds of cryptic 3’ splice sites (3’SSs) are used in cancers with SF3B1mutations. We
define the necessary sequence context for the observed cryptic 3’ SSs and propose that
cryptic 3’SS selection is a result of SF3B1mutations causing a shift in the sterically pro-
tected region downstream of the branch point. While most cryptic 3’SSs are present at low
frequency (<10%) relative to nearby canonical 3’SSs, we identified ten genes that preferred
out-of-frame cryptic 3’SSs. We show that cancers with mutations in the SF3B1HEAT 5-9 re-
peats use cryptic 3’SSs downstream of the branch point and provide both a mechanistic
model consistent with published experimental data and affected targets that will guide fur-
ther research into the oncogenic effects of SF3B1mutation.
Author Summary
A key goal of cancer genomics studies is to identify genes that are recurrently mutated at a
rate above background and likely contribute to cancer development. Many such recurrent-
ly mutated genes have been identified over the last few years, but we often do not know the
underlying mechanisms by which they contribute to cancer growth. Unexpectedly, several
genes in the spliceosome, the collection of RNAs and proteins that remove introns from
transcribed RNAs, are recurrently mutated in different cancers. Here, we have examined
mutations in the splicing factor SF3B1, a key component of the spliceosome, and identified
a global splicing defect present in different cancers with SF3B1mutations by comparing
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the expression of splice junctions using generalized linear models. While prior studies
have reported a limited number of aberrant splicing events in SF3B1-mutated cancers, we
have established that SF3B1mutations are associated with usage of hundreds of atypical
splice sites at the 3’ end of the intron. We have identified nucleotide sequence require-
ments for these cryptic splice sites that are consistent with a proposed mechanistic model.
These findings greatly expand our understanding of the effect of SF3B1mutations on
splicing and provide new targets for determining the oncogenic effect of SF3B1mutations.
Introduction
One of the biggest surprises to emerge from the growing catalog of somatic mutations in vari-
ous cancer types is the recurrent mutation of genes encoding the RNA spliceosome [1]. Recur-
rent mutations in the highly conserved HEAT 5–9 repeats of splicing factor 3B subunit 1
(SF3B1) have been reported in myelodysplastic syndrome, chronic lymphocytic leukemia
(CLL), breast cancer (BRCA), uveal melanoma (UM), and pancreatic cancer [2–7]. SF3B1mu-
tation is associated with poor prognosis in CLL but improved prognosis in myelodysplasia and
UM [2,7–9]. Prior studies have shown that mutated SF3B1 CLL samples have differential exon
inclusion and use some cryptic 3’ splice sites (3’SSs) relative to wild-type SF3B1 CLL samples
[5,6,8,10,11]. However, it is unknown whether SF3B1mutation is associated with the same 3’SS
selection defects in different cancers. The mechanism underlying the cryptic 3’SS selection and
the functional consequences thereof remain unresolved as well.
SF3B1 is a core part of the U2-small nuclear ribonucleoprotein (U2-snRNP) complex and
stabilizes the binding of the U2-snRNP to the branch point (BP), a degenerate sequence motif
usually located 21–34 bp upstream of the 3’SS [12,13]. SF3B1 also interacts with other spliceo-
somal proteins such as U2AF2, which binds the polypyrimidine tract (PPT) downstream of the
BP [2,14,15]. The binding of the U2-snRNP and other spliceosome proteins around the BP pre-
vents 3’SS selection in a ~12–18 bp region directly downstream of the BP due to steric hin-
drance [16,17]. Inherited cis-acting splicing mutations beyond this ~12–18 bp region
downstream of the BP that result in the use of cryptic 3’SSs have been shown to occur in Men-
delian disease genes [18]. Additionally, a competitive region exists ~12 bp downstream from
the first 3’SS after the protected region where AG dinucleotides can compete to be used as
3’SSs based on sequence characteristics such as the PPT length, distance from the BP, nucleo-
tide preceding the AG dinucleotide, and other features [17].
The role of SF3B1 and the U2-snRNP in recognizing and binding the BP and the localiza-
tion of mutations to HEAT 5–9 repeats suggest that SF3B1mutations are dominant drivers
that may alter 3’SS selection [6]. To test this, we examined splice site usage in transcriptome
data from SF3B1mutant and SF3B1 wild-type CLL, UM and BRCA cases. We identified 619
cryptic 3’SSs used more frequently in SF3B1mutants and clustered 10–30 bp upstream of ca-
nonical 3’SSs. The majority of these cryptic 3’SSs were observed in all three tumor types despite
the divergent clinical implications of SF3B1mutation. Our analysis of tumors with SF3B1mu-
tations shows that cryptic 3’SS selection occurs only in samples with missense mutations at
~10 amino acid hotspots in the fifth to ninth HEAT repeats. We analyzed the organization of
splicing motifs around the cryptic 3’SSs and found that only introns with an AG dinucleotide
at the boundary of the sterically protected region downstream of the BP but>10 bp upstream
of the canonical 3’SS are susceptible to cryptic 3’SS selection in SF3B1mutants. We assessed
the functional impact of SF3B1mutation and found that the cryptic 3’SSs are typically used at
low frequency in the SF3B1mutants (<10% relative to the canonical splice site) and are
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sometimes present in the SF3B1 wild-types but at an even lower frequency (<0.5% relative to
the canonical splice site). However, we identified 10 candidate genes, some previously implicat-
ed in tumorigenesis, for which there is a high amount of out-of-frame cryptic splice site usage
that may affect the function of these genes.
Results
Cryptic 3’ splice sites 10–30 bp upstream of canonical 3’ splice sites are
used in SF3B1mutants
We used RNA-sequencing data from SF3B1mutated and SF3B1 wild-type chronic lymphocytic
leukemia (CLL; seven mutant, nine wild-type), breast cancer (BRCA; 14 mutant, 18 wild-type),
and uveal melanoma (UM; four mutant, four wild-type) samples (S1 Fig., S1 File) to test
219,476 splice junctions present in the Gencode v14 gene annotation [19] along with 87,941 novel
splice junctions (not annotated in Gencode) for differential usage by comparing junction-span-
ning reads using a generalized linear model as implemented in DEXSeq [20]. A splice junction is
considered differentially used between mutant and wild-type samples if the expression level of
that junction differs significantly after accounting for overall expression differences of the corre-
sponding gene locus. All tested junctions were covered by at least 20 reads summed over all cancer
samples in a given analysis, shared a 5’ splice site and/or 3’SS with a Gencode splice junction, and
had a known splice site motif. We identified 1,749 junctions that were significantly differentially
used between the SF3B1mutant and SF3B1 wild-type samples across the three tumor types in-
cluding 1,330 novel junctions, of which 1,117 are novel 3’SSs (BH-adjusted p< 0.1, S2 File).
These 1,749 significant junctions were highly enriched for novel splice junctions compared to an-
notated junctions (Fisher exact, p< 10-200) and the novel junctions were enriched for novel 3’SSs
(Fisher exact, p< 10-200) showing that SF3B1mutations result in the usage of a large number of
novel 3’SSs. These 1,749 significant junctions include 61 of 79 splice sites recently reported as spe-
cific to CLL cases with SF3B1mutations [11] supporting the specificity of our approach while
demonstrating an increased sensitivity that has allowed us to identify many more cryptic 3’SSs
than previously reported. We plotted the distance between each significant novel 3’SS and its asso-
ciated canonical 3’SS (defined as the nearest Gencode 3’SS that shared the same 5’ splice site—see
Methods). Of the 1,117 significant novel 3’SSs, 619 were proximal cryptic 3’SSs clustered 10–30
bp upstream of their associated canonical 3’SSs while the remaining 498 cryptic 3’SSs were widely
distributed (herein referred to as distal cryptic 3’SSs) (Fig. 1A, S3 File). All of the 619 proximal
cryptic 3’SSs were used more often in the SF3B1mutant samples compared to the wild-type sam-
ples and 58% were out-of-frame relative to the nearby canonical 3’SSs, suggesting that these are
not canonical 3’SSs missing from Gencode. 417 of the 498 distal cryptic 3’SSs were also used more
highly in the SF3B1mutants (S4 File). The distribution of the 1,117 significant novel 3’SSs is dif-
ferent from that of novel 3’SSs whose usage did not differ significantly between the SF3B1mutants
and wild-types (Fig. 1B,C), further demonstrating that the usage of proximal cryptic 3’SSs is a
property of SF3B1mutants. Examining each tumor type individually, we observed the same en-
richment of cryptic 3’SSs 10–30 bp upstream of canonical splice sites (S2 Fig.). Given these obser-
vations, SF3B1’s role in binding the BP, and the organization of the BP and splicing motifs in the
last 30 bp of the intron [12], we focused our initial analyses on the 619 proximal cryptic 3’SSs.
Cryptic 3’SS selection is limited to tumors with mutations in HEAT repeat
hotspots
We clustered all samples based on the read coverage of the 619 proximal cryptic 3’SSs and
found that four SF3B1-mutated BRCA samples did not cluster with the other mutants
SF3B1 Mutations and Cryptic 3’ Splice Site Usage
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Fig 1. Proximal cryptic 3’SSs used significantly more often in cancers with SF3B1 hotspot mutations. log2 distance in base pairs from associated
canonical 3’SSs to (A) 1,117 significantly differentially used novel 3’SSs, (B) 16,673 novel 3’SSs with canonical intron motifs (GT/AG) used more highly in the
mutants but not significant, and (C) 18,660 novel 3’SSs with canonical intron motifs (GT/AG) used more highly in the wild-types but not significant. Zero
represents the position of the canonical 3’SS. Negative and positive distances indicate that the cryptic 3’SS is respectively upstream or downstream from the
canonical 3’SS. Inset in (A) shows base-by-base binning from zero to 50 base pairs upstream of canonical 3’SS. Red and blue histograms represent
junctions with significantly higher usage in SF3B1mutants or SF3B1wild-type samples, respectively. (D) Upper red and blue heatmap shows for each
sample the log2 library-normalized count z-score for 619 cryptic 3’SSs used significantly more often in the SF3B1mutants and located 10–30 bp upstream of
canonical 3’SSs (DEXSeq, BH-adjusted p< 0.1). Grey bars at left indicate frequency of SF3B1mutant allele in RNA-seq data. Colorbars indicate SF3B1
mutation status, cancer type, and whether the SF3B1mutation is located in the HEAT 5–9 repeats. Black and white colorbar indicates whether novel 3’SSs
are out-of-frame (black) relative to canonical 3’SSs. Bottom green heatmap shows relative expression levels for the genes containing each cryptic 3’SS. We
calculated the average expression of each gene in each cancer type and normalized by the maximum expression for each gene so that the maximum value
in each column is one (see Methods). Cryptic 3’SSs not observed in all cancer types tend to have differing gene expression levels between cancers. (E)
Locations and frequency of SF3B1mutations in HEAT repeats 5–9. Mutations observed more than once in COSMIC (upper axis) cluster in ~10 amino acid
hotspots in each HEAT repeat; most frequent mutation in each hotspot is labeled. Bottom axis shows locations and frequency of mutations in our study.
BRCA samples with A663V and Y765Cmutations do not show evidence for cryptic 3’SS selection.
doi:10.1371/journal.pcbi.1004105.g001
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(Fig. 1D). The SF3B1mutation for one of these BRCA samples was a nonsense mutation not lo-
cated in the HEAT 5–9 repeats while another sample had a subclonal (8.4%) HEAT 5–9 muta-
tion with attenuated cryptic 3’SS selection (S3 Fig.). The other two samples had mutations in
the HEAT 5–9 repeats but outside of the apparent ~10 amino acid mutational hotspots
(Fig. 1E). We observed cryptic 3’SS selection in a TCGA lung adenocarcinoma sample with a
hotspot mutation but not in lung cancer samples with SF3B1mutations outside of the five hot-
spots (S4 Fig.). These results show that cryptic 3’SS selection only occurs in tumors carrying
mutations in one of the five ~10 amino acid hotspots in the HEAT 5–9 repeats and is not limit-
ed to cancers in which SF3B1 is recurrently mutated.
Cryptic 3’SSs are shared across different cancer types
The majority of the 619 proximal cryptic 3’SSs were used in SF3B1-mutated samples in all
three cancer types suggesting that the mechanism of cryptic 3’SS selection in SF3B1-mutated
tumors is the same between different cancers (Fig. 1D). Some cryptic 3’SSs were not used in
one or two of the cancer types due to lower expression of the corresponding genes in those can-
cers. Differences in cryptic 3’SS usage due to varying gene expression may contribute to the di-
vergent prognostic implications of SF3B1mutation in various cancers [2,7].
To characterize the roles of the genes affected by cryptic 3’SS usage, we performed a gene set
enrichment analysis for the 912 genes that contained the 619 proximal and 417 distal cryptic
3’SSs used significantly more often in the SF3B1mutant samples (S5 File). The gene set with
the second smallest p-value consists of genes up-regulated in chronic myelogenous leukemia
and the seventh gene set contains genes up-regulated in aggressive uveal melanoma samples
(GSEA [21], q< 10-35). These results may reflect the fact that we are more likely to identify
cryptic 3’SSs in genes that are highly expressed which may bias such a gene set enrichment
analysis. Nonetheless, several gene sets with potential importance for cancer development are
enriched such as genes positively correlated with BRCA1, ATM, and CHEK2 expression across
normal tissues (GSEA, q< 10-28).
Cryptic 3’SSs are located ~13–17 bp downstream of the branch point
We characterized the sequence features of the 619 proximal cryptic 3’SSs and their associated
canonical 3’SSs to gain further insights into the mechanism of cryptic 3’SS selection (Fig. 2A).
We chose 23,066 control 3’SSs (see Methods) and plotted the nucleotide frequency [22] for the
last 50 bp of the introns for all control, associated canonical, and cryptic 3’SSs as well as the en-
richment of adenines relative to the control introns. The control introns have a typical nucleo-
tide composition with a 4–24 bp PPT preceding the 3’SS (Fig. 2B) [13]. The associated
canonical 3’SS introns are enriched for adenines ~15–20 bp upstream of the 3’SS since the
proximal cryptic 3’SSs are located in this region (Fig. 2C). However, the introns for proximal
(Fig. 2D) and distal (Fig. 2E) cryptic 3’SSs have a strong enrichment of adenines concentrated
~15 bp upstream of the splice sites. These results suggest that the increased usage of the 619
proximal and 417 distal cryptic 3’SSs in the SF3B1mutants may result from the same mecha-
nism. The human BP motif is highly degenerate except for a largely invariant adenine [13]
leading us to suspect that the adenine signal upstream of the cryptic 3’SSs is caused by the asso-
ciated canonical 3’SSs’ BP adenines. We used SVM_BP [23] to predict BPs for the associated
canonical 3’SSs and calculated the distance from the highest scoring predicted BPs to the cryp-
tic splice sites. We found that AG dinucleotides that serve as cryptic 3’SSs are enriched ~13–17
bp downstream from the predicted BP (Fig. 3A) relative to random AG dinucleotides present
in control 3’SS introns (Fig. 3B, p< 10-7, MannWhitney U). For cryptic 3’SSs not located
13–17 bp downstream from the highest scoring BP in Fig. 3A, we calculated the distance from
SF3B1 Mutations and Cryptic 3’ Splice Site Usage
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004105 March 13, 2015 5 / 19
Fig 2. 3’ intron nucleotide composition for control, associated canonical, and cryptic 3’SSs. (A) We
identified 23,066 control 3’SSs whose junctions had a mean coverage greater than 100 reads over all CLL,
BRCA, and UM samples to compare to the cryptic and associated canonical 3’SSs. Nucleotide frequency for
the last 50 bp of the intron for (B) 23,066 control 3’SSs; (C) 613 associated canonical 3’SSs; (D) 619 proximal
cryptic 3’SSs; and (E) 417 distal cryptic 3’SSs. Bar plots above each nucleotide composition plot are log10 p-
SF3B1 Mutations and Cryptic 3’ Splice Site Usage
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the second highest scoring BP to the cryptic 3’SSs and found that overall, the majority of the
cryptic 3’SSs were located 13–17 bp from either the highest or second highest scoring BP
(Fig. 3C).
Proposed mechanism of cryptic 3’SS selection
3’SSs are typically not located within ~12–18 bp downstream of the BP because the proteins
bound to the BP sterically hinder AG dinucleotides in this region and prevent them from being
used as 3’SSs [16]. Our results suggest that AG dinucleotides serving as cryptic 3’SSs in SF3B1
mutants are located at the end of this sterically protected region downstream of the BP
(Fig. 3D). Additionally, during the splicing reaction, the spliceosome searches ~12 bp down-
stream from the first 3’SS after the BP for any other 3’SSs and chooses the strongest 3’SS based
on sequence features [16]. The lack of cryptic 3’SSs in the last 10 bp of the intron (Fig. 1A) indi-
cates that cryptic 3’SSs used in SF3B1mutants are located far enough upstream of the associat-
ed canonical 3’SSs to avoid competition for splicing. We observed that the distance between
associated canonical 3’SSs and their predicted BPs is significantly greater than the distance be-
tween control 3’SSs and their BPs such that the cryptic 3’SSs at the edge of the protected region
do not compete with the canonical 3’SS for splicing (p< 10-23, MannWhitney U, Fig. 3E,F).
We also predicted BP’s for the 619 proximal and 417 distal cryptic 3’SSs (as opposed to above
where we predicted BP’s for the canonical 3’SSs associated with the 619 proximal 3’SSs) and
found that the majority of these cryptic 3’SSs were 13–17 bp downstream of their predicted
BP’s (S5 Fig.) providing further evidence that most cryptic 3’SSs (both proximal and distal) as-
sociated with SF3B1mutations are located at the edge of the sterically protected region.
Our results suggest that the mechanism of cryptic 3’SS selection in SF3B1mutants is not al-
tered BP recognition because a more varied distribution of distances from the cryptic 3’SS to the
canonical 3’SS BP would be expected if BP recognition was altered. Studying the role of cryptic
3’SS in inherited Mendelian disease genes, Královicová et al. 2005 used splicing reporters with
cryptic 3’SSs located in the PPT and found that moving the cryptic 3’SS into the ~12–18 bp steri-
cally protected region reduced or eliminated cryptic 3’SS selection. On the other hand, moving
an AG dinucleotide out of the sterically protected region allowed for its selection as a cryptic
3’SS [18]. These published experimental results and the rigid distance between the BP and the
cryptic 3’SSs observed in our study are consistent with a model of altered 3’SS selection in SF3B1
mutants due to a change in the size of the sterically hindered region downstream of the BP.
To test whether the sequences requirements defined here are sufficient for cryptic 3’SS usage,
we identified 11,302 introns whose canonical 3’SSs passed our coverage cutoff of 20 reads
summed over all samples and had potential cryptic 3’SSs (intronic AG dinucleotides that were
10–30 bp upstream of an annotated 3’SS and 13–17 bp downstream of the highest-scoring pre-
dicted BP). For 900 of these introns, the potential cryptic 3’SSs also passed the coverage cutoff,
of which 310 were used significantly more often in the SF3B1mutants. This analysis demon-
strates that not every potential cryptic 3’SS is differentially used in the mutants, so the sequence
requirements described here appear to be necessary for cryptic 3’SS usage but not sufficient.
Cryptic 3’SSs are used infrequently relative to canonical 3’SSs
Although the cryptic splice sites described here are used significantly more often in the SF3B1
mutants, the biological effects are likely dependent on the proportion of transcripts that use the
values from Fisher exact tests for enrichment of adenines at each position relative to control 3’SSs.
Horizontal line marks significance level of p = 0.05. (-log10 0.05 1.3). The p-value box plots have different
scales in (C), (D), and (E); the smallest p-values for each panel are labeled.
doi:10.1371/journal.pcbi.1004105.g002
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cryptic 3’SSs relative to the canonical 3’SSs. We therefore calculated the percent spliced in
(PSI) for the proximal cryptic 3’SSs relative to their associated canonical 3’SSs in the CLL sam-
ples since they have a higher sequencing depth than the other tumor samples (S1 Fig.) that al-
lows for more accurate quantification of splicing and because the distribution of well-
characterized low- and high-risk CLL prognostic factors was similar between the SF3B1mutat-
ed and wild-type samples (Fig. 4A). To calculate PSI for the 325 proximal cryptic 3’SSs used
significantly more often in the SF3B1mutants from the CLL-only analysis (S6–S7 Files), we di-
vided the number of reads that span the cryptic 3’SS by the number of reads that span both the
cryptic 3’SS and its associated canonical 3’SS. We observed that some cryptic 3’SSs are used ex-
clusively in SF3B1mutants while others are also used in SF3B1 wild-type samples but at a
lower frequency relative to the mutants (Fig. 4A). 67% of the cryptic 3’SSs were included in
<10% of transcripts compared to their associated canonical 3’SS. These results suggest that the
cryptic splice sites are either included rarely even in the SF3B1mutants or that transcripts with
cryptic splice sites are subject to a higher rate of nonsense-mediated decay (NMD). To investi-
gate the potential role of NMD, we identified differentially expressed genes between the SF3B1
mutant and wild-type samples in a joint analysis of all three cancers and performed a gene set
enrichment analysis. We found that genes in the “Reactome NMD enhanced by the exon junc-
tion complex” set were enriched (GSEA [21], q< 10-28) among the 272 differentially expressed
genes (DESeq2, BH-adjusted p< 0.1, S8–S9 Files) suggesting that NMDmay be different be-
tween the SF3B1mutants and wild-types. 33 of the 582 genes that contained the 619 proximal
Fig 3. Location of predicted branch point relative to cryptic and canonical 3’SSs andmodel of cryptic 3’SS selection. (A) Distance from highest
scoring BP predicted for associated canonical 3’SSs to the corresponding proximal cryptic 3’SSs. A negative distance indicates that the cryptic 3’SS is
upstream of the BP predicted for the canonical 3’SS. The small spike at 2 bp indicates that in a few cases the adenine in the cryptic 3’SS is predicted to be the
BP adenine for the canonical 3’SS. (B) Distance from highest scoring BP predicted for control 3’SSs to downstream intronic AG dinucleotides that are not
annotated as 3’SSs. (C) Distance from either highest or second highest scoring BP predicted for canonical 3’SSs to their associated cryptic 3’SSs (see
Methods). (D) Model for proximal cryptic 3’SS selection in SF3B1mutants. yTnAy is the human BPmotif. AG dinucleotides located at the edge of the
sterically protected region can be used as 3’SSs in SF3B1mutants (star). AG dinucleotides located in the protected or competitive regions (X’s) are
respectively sterically hindered from being selected as 3’SSs or out-competed by the canonical 3’SS. Distance from predicted BP to 3’SS for (E) associated
canonical 3’SSs and (F) control 3’SSs (see Methods) is significantly different (p< 10-23, MannWhitney U).
doi:10.1371/journal.pcbi.1004105.g003
SF3B1 Mutations and Cryptic 3’ Splice Site Usage
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004105 March 13, 2015 8 / 19
cryptic 3’SSs were differentially expressed with the expression of 29/33 of these genes lower in
the SF3B1mutants. Genes containing a proximal cryptic 3’SSs were more likely to be differen-
tially expressed (Fisher exact, p< 10-8) and more likely to have lower expression in SF3B1mu-
tants (Fisher exact, p = 0.0009). These results suggest that cryptic 3’SS selection may affect gene
expression for a subset of genes. However, the observation that in-frame cryptic 3’SSs likely not
subject to NMD and out-of-frame cryptic 3’SSs potentially subject to NMD are included at
similar rates relative to their associated canonical 3’SSs (Fig. 4A) suggests that most genes’ ex-
pression are not affected by cryptic 3’SS selection and most cryptic 3’SSs are observed at a low
frequency because they are spliced in infrequently compared to their associated canonical
3’SSs.
To identify cryptic 3’SSs with relatively high PSI values in the SF3B1mutant versus wild-
type samples, we searched for cryptic 3’SSs that were 1) used more than 50% of the time in the
CLL SF3B1mutants; 2) used less than 20% of the time in wild-type samples; and 3) had an av-
erage coverage of at least 30 junction-spanning reads in the mutant samples. Despite the gener-
ally low PSI values for the 325 cryptic 3’SSs from the CLL-only analysis, we identified four
genes previously implicated in cancer (TTI1 [24–26],MAP3K7 [27–29], FXYD5 [30], PFDN5
[31]) and six others (YIF1A, ORAI2, ZNF91, ZNF548, RP11–1280I22.1, RP11–532F12.5) with
out-of-frame cryptic 3’SSs that were consistently preferred to the associated canonical 3’SS in
Fig 4. Percent spliced in for cryptic 3’ splice sites in CLL analysis. (A) Heatmap shows the percent spliced in (PSI) values for cryptic 3’SS relative to the
canonical 3’SS in CLL SF3B1mutated or wild-type samples for 325 proximal cryptic 3’SSs used significantly more often in the CLL mutants (DEXSeq, BH-
adjusted p< 0.1). SF3B1mutation presence and the status of prognostic factors IGHV and ZAP70 are shown in left colorbars. Black and white colorbar
indicates whether novel 3’SSs are out-of-frame (black) relative to canonical 3’SSs. In-frame and out-of-frame cryptic 3’SSs are used at similar rates relative
to their associated canonical 3’SSs. (B) Beeswarm plots indicating the PSI values for the cryptic 3’SS relative to the associated canonical 3’SS in ten genes
with high levels of cryptic 3’SS inclusion in CLL SF3B1mutants (M) compared to wild-type (W) samples. No reads were observed spanning the cryptic YIF1A
junction in any wild-type CLL samples. The number in the upper corner of each plot is the distance in base pairs from the highest or second-highest scoring
BP predicted for the associated canonical 3’SS to the cryptic 3’SS.
doi:10.1371/journal.pcbi.1004105.g004
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the CLL SF3B1mutant samples (Fig. 4B). Ferreira et al. identified the junctions in ORAI2,
ZNF91, and TTI1 in CLL SF3B1mutants as well [11]. Nine of the ten junctions were significant
in our BRCA-only analysis and showed high differences in relative inclusion (S6 Fig., S10–S11
Files). These genes are not differentially expressed between the CLL SF3B1mutant and wild-
type samples (S12 File) but the frequent inclusion of out-of-frame cryptic 3’SSs may affect their
biological function.
Discussion
Here we have shown that a consequence of SF3B1mutations in different cancer types is ge-
nome-wide selection of hundreds of cryptic 3’SSs. We have shown the cryptic 3’SSs have specific
sequence requirements; AG dinucleotides used as cryptic 3’SSs in SF3B1mutants are located at
the end of the sterically protected region ~13–17 bp downstream of the BP but are>10 bp up-
stream of nearby canonical 3’SSs allowing them to avoid competition for splicing. These se-
quence requirements limit the introns susceptible to cryptic 3’SS selection to those where the BP
is located farther from the 3’SS than the typical ~24 bp. While these requirements appear neces-
sary for cryptic 3’SS usage, they are not sufficient, as we did not detect cryptic 3’SS usage in all
introns with AG dinucleotides that satisfy these requirements. Characteristics such as RNA con-
formation, RNA binding protein sites, BP prediction inaccuracies, cryptic or downstream ca-
nonical 3’SS strength, gene/transcript expression, sequencing depth, or other factors may also
play a role in determining whether cryptic 3’SSs are used and detected by RNA sequencing.
Examining differential splice junction usage allowed us to identify many more cryptic 3’SSs
than previous studies while still identifying 61 of 79 cryptic 3’SSs recently reported for CLL
SF3B1mutants using a method based on relative inclusion [5,6,8,10,11]. When examining the
three cancer types in our study individually, the number of cryptic 3’SSs identified was highly
dependent on the sequencing depth of the samples (S1–S2 Figs., S2 File). Additionally, examin-
ing cryptic 3’SSs expressed higher in the SF3B1mutants but not significantly (Fig. 1B) shows a
modest enrichment of novel 3’SSs 10–30 bp upstream of canonical 3’SSs. These observations
suggest that deeper sequencing will continue to reveal proximal cryptic 3’SSs in SF3B1mutants
that are used very infrequently or are present in lowly expressed genes.
Selection of cryptic 3’SSs in the region downstream of the BP has been reported for some in-
herited diseases including those resulting from disrupted tumor suppressor genes such as ATM,
NF1, and TP53 [18]. Using a curated a list of aberrant splice sites associated with different dis-
eases from the literature, Královicová et al. 2005 found that in cases where cryptic 3’SS selection
was not caused by mutation of the 3’YAG consensus sequence, cryptic 3’SSs were often located
~19 bp upstream of associated canonical 3’SSs and ~11–15 bp downstream of the BP [18]. Most
of the diseases considered in Královicová et al. 2005 are Mendelian diseases where a cryptic 3’SS
disrupts or abolishes the function of a single disease gene. In these cases, a mutation in the PPT
between the sterically protected and competitive regions has introduced a cryptic 3’SS
(Fig. 3D). For cancers with SF3B1mutations, we suspect that the size of the sterically protected
region is slightly altered allowing for existing AG dinucleotides to be used as cryptic 3’SSs in
hundreds of genes. It is also possible SF3B1mutations could cause destabilization of the U2
snRNP complex or alter interactions with U2AF2, affecting the ability to recognize the canoni-
cal 3’SS and leading to cryptic 3’SS selection. However, the rigid distance (~13–17 bp) from the
predicted BPs to the cryptic 3’SSs for most of the cryptic 3’SSs is most consistent with a change
in the size of the sterically protected region downstream of the branch point.
We found that cryptic 3’SS selection is limited to tumors with mutations in the five ~10
amino acid hotspots in the SF3B1 HEAT 5–9 repeats and that these mutations are associated
with cryptic 3’SS selection across different cancer types and even in cancers in which SF3B1 is
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not recurrently mutated. 58% of these cryptic 3’SSs are out-of-frame relative to nearby canoni-
cal 3’SSs, but the biological impact of these cryptic 3’SSs is likely a function of how frequently
they are used relative to the nearby canonical 3’SSs. We found that while the cryptic 3’SSs are
used more often in the SF3B1mutated samples compared to wild-type samples, they are used
relatively infrequently (<10%) compared to nearby canonical 3’SSs. While the differentially ex-
pressed genes between the SF3B1mutated and wild-type samples are enriched for genes in the
NMD pathway, even in-frame cryptic 3’SSs are used at a low frequency indicating that the asso-
ciated canonical 3’SS is mostly preferred to the cryptic 3’SS even in SF3B1mutants. Nonethe-
less, we identified ten genes, including four with known roles in cancer, which had a high
frequency of cryptic splice site usage relative to the nearby canonical splice site. Further studies
are required to determine whether low-frequency cryptic 3’SS selection in hundreds of genes,
high-frequency cryptic 3’SS selection in a small group of genes, and/or other splicing alter-
ations drive the oncogenic effect of SF3B1mutation.
Methods
Sample selection
Ethics statement. For the chronic lymphocytic leukemia (CLL) samples, the UCSD IRB ap-
proved the study and all subjects gave informed consent (Project #080918). Refer to the in-
formed consent for The Cancer Genome Atlas and Harbour et al. for consent information for
other cancer samples [7].
CLL. Seven SF3B1-mutated CLL cases and nine SF3B1 wild-type CLL cases were identified
from the CLL Consortium database. The mutations were originally characterized by PCR and
verified in the RNA-sequencing data [9]. Sample dates were chosen on average 95 days prior to
treatment and at least 287 days after prior treatment to select samples with high tumor cell
count. Samples were chosen to have relatively similar numbers of IGHVmutated/unmutated
and ZAP-70 positive/negative samples (Fig. 4).
BRCA, LUAD, and LUSC. SF3B1mutant samples were identified using the Broad GDAC
TCGA analysis (http://gdac.broadinstitute.org/runs/analyses__2013_02_22/) in TCGA tumor
types with no publication restrictions. Samples with SF3B1mutations outside of Gencode ver-
sion 14 exons were excluded. We excluded any cancer types with less than four SF3B1mutants
or for which paired-end RNA-sequencing data was not available leaving breast cancer (BRCA),
lung adenocarcinoma (LUAD), and lung squamous cell carcinoma (LUSC). We chose 1.25 as
many SF3B1 wild-type controls as mutated samples for each cancer type randomly from sam-
ples without mutations in SF3B1 or other splicing factors. RNA sequencing data was down-
loaded from CGHub [32].
UM. Uveal melanoma samples were downloaded from the Short Read Archive
(SRA062359) [7]. As reported in Furney et al., four uveal melanoma samples had SF3B1muta-
tions in codon 625 and four had wild-type copies of SF3B1 [33].
Library preparation and sequencing for CLL samples
RNA was extracted from peripheral blood mononucleocytes from seven SF3B1-mutated CLL
cases and nine SF3B1 wild-type cases per the manufacturer’s specifications using Qiagen
RNeasy mini-spin columns, and RIN scores determined using an Agilent Bioanalyzer. RNA
was polyA selected and processed using SMART cDNA synthesis (Clontech) to prepare se-
quencing libraries. Samples were sequenced on Illumina HiSeq2000 instruments generating an
average of 239 million paired 75 bp reads per sample (S1 Fig.).
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Adapter trimming
Sequencing adapters and poly-A/T tails were trimmed for CLL samples only using cutadapt
version 1.1 (-m 20—n 10—b AAGCAGTGGTATCAACGCAGAGTACTTTTTTTTTTT—b
AAGCAGTGGTATCAACGCAGAGTACGCGGG—b AAGCAGTGGTATCAACGCAGAGT
—b
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-
TTTTTTTTTTTTTTT—b
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA-
AAAAAAAAAAAAAAAAAAAAA) [34]. Read pairs where or one of both reads were of
length less than 20 were removed.
Read alignment
RNA-seq reads were aligned to the human genome (hg19) using STAR 2.3.0e (—alignSJDBo-
verhangMin 1—seedSearchStartLmax 12—alignSplicedMateMapLminOverLmate 0.08—out-
FilterScoreMinOverLread 0.08—outFilterMatchNminOverLread 0.08—
outFilterMultimapNmax 100—outFilterIntronMotifs RemoveNoncanonicalUnannotated—
outSJfilterOverhangMin 6 6 6 6) and a splice junction database consisting of junctions from
Gencode, UCSC knownGene, AceView, lincRNAs, and H-Inv [19,35–39]. Duplicate read pairs
were removed prior to alignment by comparing the sequences of all read pairs and keeping
only one read pair per set of read pairs with identical sequences.
Splice junction read coverage
Splice junction read coverages were obtained from the SJ.out.tab output file from STAR.
Novel splice junction identification
Novel splice junctions were defined as those junctions identified by STAR not present in Gen-
code version 14 that (i) were covered by at least 20 reads summed over all cancer samples in a
given analysis, (ii) shared a 5’ splice site and/or 3’SS with a Gencode junction, and (iii) had one
of the following motifs: GU/AG, CU/AC, GC/AG, CU/GC, AU/AC, GU/AU. Novel junctions
were calculated separately for each analysis.
Splice junction usage
Known and novel junctions that had a coverage of at least 20 reads over all samples, used a
known intron motif, and contained a known Gencode 5’ splice site or 3’SS were aggregated by
gene and tested for differential usage using DEXSeq’s testForDEUTRT function (v1.8.0, R v3.0.3)
[20]. Splice junctions used in more than one Gencode gene were removed. When multiple cancer
types were analyzed, we provided cancer type as a covariate to DEXSeq. Raw p-values were ad-
justed for multiple hypothesis testing using the Benjamini Hochberg procedure. To examine the
impact of the coverage cutoff of 20 reads summed over all samples on our results, we increased
the cutoff to 50, 75, and 100 reads summed over all samples and found that 42%, 32%, and 24%
of the significant novel 3’SSs remained at each of these cutoffs. The enrichment for proximal
cryptic 3’SS remained at all cutoffs, so we used the 20 read cutoff to maximize sensitivity.
Identification of associated canonical 3’SSs for cryptic 3’SSs
Associated canonical 3’SSs were identified for novel/cryptic 3’SSs as follows. First, all Gencode
splice sites that shared a 5’ splice site with the novel 3’SS were identified. Then, the closest Gen-
code 3’SS from these splice sites that was downstream of the cryptic 3’SS was chosen as the
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associated canonical 3’SS for that cryptic 3’SS. If there was no Gencode 3’SS downstream of the
cryptic 3’SS, the closest Gencode 3’SS upstream of the cryptic 3’SS was chosen as the associated
canonical 3’SS.
Gene set enrichment for genes with cryptic 3’SS usage
We performed a gene set enrichment analysis using GSEA [21] for the genes that contained
cryptic 3’SSs by combining the genes that contained the 619 proximal (S3 File) and the 417 dis-
tal cryptic 3’SSs (S4 File).
Identification of control 3’SSs
We identified 23,066 control 3’SSs by choosing splice sites that are annotated in Gencode,
whose average coverage over BRCA, CLL, and UM samples is greater than 100, and whose 5'
splice site does not have any novel 3'SSs. We characterized intronic AG dinucleotides for these
control junctions by analyzing the intronic sequence downstream of the predicted branch
points minus the last 10 bp of the intron since alternative 3’SSs can be located in the last 10 bp
of the intron.
Hierarchical clustering
All heatmap rows and columns were clustered using scipy.cluster.hierarchy.linkage with either
the “complete” or “single” distance metric.
SF3B1mutant allele frequency
Mutant allele frequency was determined by calculating per-base coverages using unique prop-
erly paired reads with samtools mpileup for the SF3B1 locus and counting the number of reads
supporting either the reference or alternate alleles.
Gene expression
Reads that were not contained within Gencode v14 exons in the STAR genomic alignment
were discarded. The remaining reads were re-aligned to the Gencode v14 transcriptome using
Bowtie2 (v2.1.0,-t-k 400-X 400—no-mixed—no-discordant) and transcript expression was es-
timated using eXpress (v1.3.0,—max-indel-size 20) [40,41]. Gene expression was estimated by
summing together the effective counts or FPKM values for all transcripts contained in a gene.
Relative average expression of genes with cryptic 3’SSs
For the green heatmap in Fig. 1D, the average expression (FPKM) of each gene containing a
cryptic 3’SS was determined for each cancer type. The average expression values were then nor-
malized for each gene by dividing by the largest average expression of the three cancers for that
gene. Therefore each column in the green heatmap in Fig. 1D has one value of 1.0 while the
other two values are between 0.0 and 1.0 and represent the expression of the gene in that cancer
relative to the maximum.
Definition of HEAT repeats
HEAT repeat locations were defined according to the definition of HEAT repeats in Wang
et al. 1998 [15].
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COSMIC SF3B1 mutations
COSMIC v66 complete export was downloaded and the number of mutations at each location
in the SF3B1 heat domains 5–9 was plotted for locations with at least two observed mutations
in COSMIC [42].
Nucleotide frequency plots
Nucleotide frequency plots were constructed using WebLogo (unit_name = ’probability’) [22].
Adenine enrichment was calculated by counting the number of adenines and non-adenines at
each intron position for a given splice site class and comparing to the number of adenines and
non-adenines in control 3’SSs using a Fisher exact test.
Branch point identification
SVM_BP was used to predict branch points [23]. The SVM_BP code was altered to allow for
branch points eight bp from the 3’SS by setting mindist3ss = 8 in svm_getfeat.py (see https://
github.com/cdeboever3/svm-bpfinder). SVM_BP was run with options “Hsap 50.”When mul-
tiple branch points were predicted for one 3’SS, we chose the branch point with the highest se-
quence score (bp_scr). In some instances, there was more than one cryptic 3’SS associated with
a canonical 3’SS, so we randomly chose only one of these cryptic splice sites for further analysis.
For Fig. 3C, we plotted the distance from highest scoring BP predicted for canonical 3’SSs to
their associated cryptic 3’SSs as in Fig. 3A. However, the distances for cryptic 3’SSs located less
than 13 bp or more than 17 bp from the BP in Fig. 3A were replaced with the distance from the
second highest scoring BP. S5C–S5D Fig. were created similarly.
Differential gene expression
Gene expression was estimated as described above. We summed the effective counts from eX-
press for all transcripts from each gene to obtain effective read counts for each gene. We pro-
vided these read counts to DESeq2 (v1.2.10, R v3.0.3) and tested for differential gene
expression using nbinomWaldTest using cancer type as a covariate for the analysis with differ-
ent cancers [43]. We only tested genes where the sum of effective read counts over all samples
was greater than 100. p-values were adjusted using the Benjamini-Hochberg procedure. Gene
set enrichment analysis was performed using GSEA [21].
Percent spliced in for cryptic 3’SSs relative to associated canonical
3’SSs
Percent spliced in (PSI) values for cryptic 3’SSs relative to canonical 3’SSs were calculated by di-
viding the number of reads that span the cryptic 3’SS (c) by the number of reads that span the
cryptic 3’SS plus the number of reads that span the canonical 3’SS (a), c
cþa, for each sample. The
ten 3’SSs with high PSI values in CLL were identified by identifying cryptic 3’SSs whose median
PSI was greater than 50% in the CLL SF3B1mutants but less than 20% in the wild-type samples
and whose average coverage was at least 30 junction-spanning reads in the CLL mutant sam-
ples. These junctions were also chosen to be out-of-frame although the cryptic 3’SS in ORAI2 is
located in the 5’ untranslated region.
Code, data, and reproducibility
We have made the code and intermediate data files needed to replicate this study available on
Github (https://github.com/cdeboever3/deboever-sf3b1-2015) and Figshare (http://dx.doi.org/
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10.6084/m9.figshare.1120663). Instructions are provided in the Github repository for repro-
ducing our figures, tables, and statistical analyses. Sequencing data is available through dbGaP
(phs000767).
Supporting Information
S1 Fig. Number of uniquely mapped RNA-seq reads from STAR alignment.We sequenced
the transcriptomes of peripheral blood mononucleocytes from seven SF3B1-mutated chronic
lymphocytic leukemia (CLL) cases and nine SF3B1 wild-type cases. We also obtained data
from breast cancer (BRCA; 14 mutant, 18 wild-type), lung squamous cell carcinoma (LUSC;
four mutant, five wild-type) and lung adenocarcinoma (LUAD; seven mutant, nine wild-type)
samples from the TCGA and uveal melanoma (UM; four mutant, four wild-type) samples
from Harbour et al. 2013.
(TIF)
S2 Fig. Proximal cryptic 3’SSs in individual cancer analyses. log2 distance in base pairs from
280, 1,476, and 86 significantly differentially used novel 3’SSs (S2 File) to their associated ca-
nonical 3’SSs in (A) BRCA, (B) CLL, and (C) UM analyses respectively. Novel 3’SSs were asso-
ciated with canonical 3’SSs only if they shared the same 5’ splice site. Zero represents the
position of the canonical 3’SS. Negative and positive distances indicate that the cryptic 3’SS is
respectively upstream or downstream from the canonical 3’SS. Inset shows base-by-base bin-
ning from zero to 50 base pairs upstream of canonical 3’SS. Red and blue histograms represent
junctions with significantly higher usage in SF3B1mutants or SF3B1 wild-type samples respec-
tively. The number of cryptic 3’SS identified varied with the overall sequencing depth of the dif-
ferent data sets.
(TIF)
S3 Fig. Breast cancer proximal cryptic 3’SS coverage.Heatmap shows for each BRCA sample
the log2 library-normalized count z-score for 192 proximal cryptic 3’SSs used significantly
more often in the SF3B1mutants and located 10–30 bp upstream of canonical 3’SSs (S2 File).
SF3B1mutants are labeled with the observed missense or nonsense () mutation as well as the
frequency of the mutant allele in the RNA-sequencing data. Attenuated cryptic 3’SS selection is
visible for the K700E mutant with only 8.4% allele frequency. A633V and Y765C mutants do
not show evidence for cryptic 3’SS selection. Black and white colorbar indicates whether novel
3’SSs are out-of-frame (black) relative to canonical 3’SSs.
(TIF)
S4 Fig. Proximal cryptic 3’SSs used significantly more often in cancers with SF3B1 hotspot
mutations including TCGA lung cancer samples.Heatmap shows for each sample the log2 li-
brary-normalized count z-score for the 578 proximal cryptic 3’SSs used significantly more
often in the SF3B1mutants in the CLL, BRCA, UM, LUAD, and LUSC joint analysis (S2 File).
Grey bars indicate frequency of SF3B1mutant allele in RNA-seq data. Colorbars indicate
SF3B1mutation status, cancer type, and whether the SF3B1mutation is located in the HEAT
5–9 repeats. Black and white colorbar indicates whether novel 3’SSs are out-of-frame (black)
relative to canonical 3’SSs.
(TIF)
S5 Fig. Cryptic 3’SSs have branch points located ~13–17 bp upstream. Distance from 3’SS to
highest scoring predicted branch point (BP). We were able to predict BPs for (A) 584 of 619
proximal cryptic 3’SSs and (B) 405 of 417 distal cryptic 3’SSs (as opposed to predicting the BPs
for the associated canonical 3’SSs as in Fig. 3). Distance from either highest or second highest
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scoring predicted BP to (C) proximal cryptic 3’SSs and (D) distal cryptic 3’SSs. Cryptic 3’SSs
that are used more often in SF3B1mutants have BPs located ~13–17 bp upstream regardless of
whether they are 10–30 bp upstream of canonical 3’SSs.
(TIF)
S6 Fig. Percent spliced in (PSI) in BRCA analysis for junctions with high PSI in CLL analy-
sis. Beeswarm plots showing the PSI values for the cryptic 3’SS relative to the associated canon-
ical 3’SS in nine of ten genes with high levels of cryptic 3’SS inclusion in CLL SF3B1mutants
(M) compared to wild-type (W) samples that were also expressed in the BRCA samples. The
number in the upper corner of each plot is the distance in base pairs from the highest or sec-
ond-highest scoring BP predicted for the associated canonical 3’SS to the cryptic 3’SS.
(TIF)
S1 File. Metadata for samples used in this study. SF3B1mutated samples have columns for
frequency of SF3B1mutation in RNA-seq data, mutation type, codon change and whether the
mutation is in the HEAT 5–9 repeats. These columns are empty for SF3B1 wild-type
tumor samples.
(TSV)
S2 File. Summary of differential junction usage results from DEXSeq. DEXSeq was used to
test for differential splice junction usage in a joint analysis of the CLL, BRCA, and UM samples
as well as individually for each cancer type. “Novel” indicates that the junction is not annotated
in Gencode. Proximal indicates that a novel 3’SS is 10–30 bp upstream of a canonical Gencode
3’SS.
(TSV)
S3 File. 619 cryptic 3’SSs located 10–30 bp upstream of canonical 3’SSs from joint BRCA,
CLL, and UM analysis. Location of 5’ splice sites and 3’SSs are one-based coordinates that de-
note the start and end of the intron. The columns COSMIC, TSgene, and ncg denote whether
the gene is present in COSMIC, TSGene, or the Network of Cancer Genes respectively.
(TSV)
S4 File. 417 distal cryptic 3’SSs used more often in SF3B1mutants from joint BRCA, CLL,
and UM analysis. Location of 5’ splice sites and 3’SSs are one-based coordinates that denote
the start and end of the intron. The columns COSMIC, TSgene, and ncg denote whether the
gene is present in COSMIC, TSGene, or the Network of Cancer Genes respectively.
(TSV)
S5 File. GSEA results for 912 genes containing 619 proximal and 417 distal cryptic 3’ splice
sites used more often in SF3B1mutants.
(XLS)
S6 File. 325 significant cryptic 3’SSs located 10–30 bp upstream of canonical 3’SSs and
used more often in SF3B1mutants from CLL-only DEXSeq analysis. Location of 5’ splice
sites and 3’SSs are one-based coordinates that denote the start and end of the intron. The col-
umns COSMIC, TSgene, and ncg denote whether the gene is present in COSMIC, TSGene, or
the Network of Cancer Genes respectively.
(TSV)
S7 File. Percent spliced in for 325 cryptic 3’SSs located 10–30 bp upstream of canonical
3’SSs from CLL-only DEXSeq analysis.Note that there are only 324 values because one ca-
nonical 3’SS was filtered due to low coverage so a PSI value could not be calculated.
(TSV)
SF3B1 Mutations and Cryptic 3’ Splice Site Usage
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004105 March 13, 2015 16 / 19
S8 File. 272 genes that are differentially expressed between SF3B1mutant and wild-type
samples from joint analysis of CLL, BRCA, and UM using DESeq2.
(TSV)
S9 File. GSEA results for 272 genes differentially expressed genes from joint CLL, BRCA,
and UMDESeq2 analysis.
(XLS)
S10 File. 192 significant cryptic 3’SSs located 10–30 bp upstream of canonical 3’SSs and
used more often in SF3B1mutants from BRCA-only DEXSeq analysis. Location of 5’ splice
sites and 3’SSs are one-based coordinates that denote the start and end of the intron. The col-
umns COSMIC, TSgene, and ncg denote whether the gene is present in COSMIC, TSGene, or
the Network of Cancer Genes respectively.
(TSV)
S11 File. Percent spliced in for 192 cryptic 3’SSs located 10–30 bp upstream of canonical
3’SSs from BRCA-only DEXSeq analysis.Note that there are only 191 values because one ca-
nonical 3’SS was filtered due to low coverage so a PSI value could not be calculated.
(TSV)
S12 File. 33 genes that are differentially expressed between SF3B1mutant and wild-type
CLL samples using DESeq2.
(TSV)
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